William L Redmond - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

William L Redmond

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

The Lancet. Oncology|August 11, 2022

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trialTomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, et al.

The Lancet. Oncology|April 10, 2018

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.

Nature Biotechnology|December 9, 2024

Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cellsEsha Madan, António M Palma, Vignesh Vudatha, et al.

Pageof 7

Search research articles

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

The Lancet. Oncology|August 11, 2022

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trialTomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, et al.

The Lancet. Oncology|April 10, 2018

Nature Biotechnology|December 9, 2024

Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cellsEsha Madan, António M Palma, Vignesh Vudatha, et al.

Pageof 7